

Applicant : Yousef Al-Abed
Appl. No. : 10/594,641
Filed : March 28, 2008

Remarks

Claims 1-11, 14-20 and 22 were pending in the subject application. By this amendment, applicant has amended Claims 1 and 3, cancelled Claims 2, 4-8, 14-20 without prejudice or disclaimer's to applicant's right to pursue prosecution of these claims in a later-filed continuation or divisional application, and added New Claims 26-28. The amendment to Claim 1 is supported by original Claim 2, Claim 3 has been amended to be dependent on Claim 1, and New Claims 26-28 are supported in the application as filed on page 12, lines 6-16. Accordingly, the amendments to Claims 1 and 3 and new Claims 26-28 do not introduce new matter, and their entry is respectfully requested.


In response to the restriction requirement set forth in the Office Action, applicant hereby elects, without traverse, to prosecute Group I, Claims 1-11. In response to the species election requirement, applicant elects an antibody (Claim 3), diabetes (Claim 9) and human (Claim 11).

No fee, other than the enclosed \$245.00 two month extension of time fee, is deemed necessary in connection with the filing of this Amendment. However, if this fee is in any way deficient, or if any additional fee is required to preserve the pendency of the subject application, authorization is hereby given to charge any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 336-8000

Dated: June 9, 2009
New York, New York

By: 
Craig J. Arnold
Registration No. 34,287